Fulcrum Therapeutics Stock Market Value
| FULC Stock | USD 3.85 0.10 2.53% |
| Symbol | Fulcrum |
Fulcrum Therapeutics Price To Book Ratio
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulcrum Therapeutics. If investors know Fulcrum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulcrum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.29) | Revenue Per Share 1.317 | Quarterly Revenue Growth 89.909 | Return On Assets (0.07) | Return On Equity (0.07) |
The market value of Fulcrum Therapeutics is measured differently than its book value, which is the value of Fulcrum that is recorded on the company's balance sheet. Investors also form their own opinion of Fulcrum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fulcrum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulcrum Therapeutics' market value can be influenced by many factors that don't directly affect Fulcrum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulcrum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulcrum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulcrum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Fulcrum Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Fulcrum Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Fulcrum Therapeutics.
| 11/01/2024 |
| 12/01/2024 |
If you would invest 0.00 in Fulcrum Therapeutics on November 1, 2024 and sell it all today you would earn a total of 0.00 from holding Fulcrum Therapeutics or generate 0.0% return on investment in Fulcrum Therapeutics over 30 days. Fulcrum Therapeutics is related to or competes with Crinetics Pharmaceuticals, Enanta Pharmaceuticals, Amicus Therapeutics, Connect Biopharma, Ligand Pharmaceuticals, Passage Bio, and Oric Pharmaceuticals. Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the... More
Fulcrum Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Fulcrum Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Fulcrum Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.09) | |||
| Maximum Drawdown | 66.11 | |||
| Value At Risk | (6.74) | |||
| Potential Upside | 9.43 |
Fulcrum Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Fulcrum Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Fulcrum Therapeutics' standard deviation. In reality, there are many statistical measures that can use Fulcrum Therapeutics historical prices to predict the future Fulcrum Therapeutics' volatility.| Risk Adjusted Performance | (0.05) | |||
| Jensen Alpha | (0.78) | |||
| Total Risk Alpha | (2.14) | |||
| Treynor Ratio | (0.79) |
Fulcrum Therapeutics Backtested Returns
Fulcrum Therapeutics secures Sharpe Ratio (or Efficiency) of -0.0604, which denotes the company had a -0.0604% return per unit of risk over the last 3 months. Fulcrum Therapeutics exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Fulcrum Therapeutics' Standard Deviation of 8.83, mean deviation of 4.22, and Variance of 77.91 to check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.85, which means possible diversification benefits within a given portfolio. As returns on the market increase, Fulcrum Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Fulcrum Therapeutics is expected to be smaller as well. At this point, Fulcrum Therapeutics has a negative expected return of -0.54%. Please make sure to confirm Fulcrum Therapeutics' treynor ratio, accumulation distribution, price action indicator, as well as the relationship between the potential upside and day median price , to decide if Fulcrum Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.63 |
Good predictability
Fulcrum Therapeutics has good predictability. Overlapping area represents the amount of predictability between Fulcrum Therapeutics time series from 1st of November 2024 to 16th of November 2024 and 16th of November 2024 to 1st of December 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Fulcrum Therapeutics price movement. The serial correlation of 0.63 indicates that roughly 63.0% of current Fulcrum Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.63 | |
| Spearman Rank Test | 0.37 | |
| Residual Average | 0.0 | |
| Price Variance | 0.14 |
Fulcrum Therapeutics lagged returns against current returns
Autocorrelation, which is Fulcrum Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Fulcrum Therapeutics' stock expected returns. We can calculate the autocorrelation of Fulcrum Therapeutics returns to help us make a trade decision. For example, suppose you find that Fulcrum Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Fulcrum Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Fulcrum Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Fulcrum Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Fulcrum Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Fulcrum Therapeutics Lagged Returns
When evaluating Fulcrum Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Fulcrum Therapeutics stock have on its future price. Fulcrum Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Fulcrum Therapeutics autocorrelation shows the relationship between Fulcrum Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Fulcrum Therapeutics.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Fulcrum Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Fulcrum Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fulcrum Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fulcrum Therapeutics Stock:Check out Fulcrum Therapeutics Correlation, Fulcrum Therapeutics Volatility and Fulcrum Therapeutics Alpha and Beta module to complement your research on Fulcrum Therapeutics. For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Fulcrum Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.